FR2888117B1 - VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION - Google Patents

VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION

Info

Publication number
FR2888117B1
FR2888117B1 FR0507240A FR0507240A FR2888117B1 FR 2888117 B1 FR2888117 B1 FR 2888117B1 FR 0507240 A FR0507240 A FR 0507240A FR 0507240 A FR0507240 A FR 0507240A FR 2888117 B1 FR2888117 B1 FR 2888117B1
Authority
FR
France
Prior art keywords
vaccine composition
thermoreversible
emulsion
thermoreversible emulsion
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0507240A
Other languages
French (fr)
Other versions
FR2888117A1 (en
Inventor
Marie Francoise Klucker
Francois Dalencon
Quellec Patricia Probeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Sanofi Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur SA filed Critical Sanofi Pasteur SA
Priority to FR0507240A priority Critical patent/FR2888117B1/en
Priority to ARP060102917A priority patent/AR054822A1/en
Priority to ES09152313T priority patent/ES2390104T3/en
Priority to DK09152313.4T priority patent/DK2080522T3/en
Priority to PT06778810T priority patent/PT1904099E/en
Priority to NZ564173A priority patent/NZ564173A/en
Priority to AT06778810T priority patent/ATE424845T1/en
Priority to US11/483,358 priority patent/US8703095B2/en
Priority to ZA200800824A priority patent/ZA200800824B/en
Priority to EA200800271A priority patent/EA012376B1/en
Priority to AP2007004280A priority patent/AP2361A/en
Priority to PT09152313T priority patent/PT2080522E/en
Priority to KR1020087002704A priority patent/KR101328638B1/en
Priority to EP06778810A priority patent/EP1904099B1/en
Priority to SI200631423T priority patent/SI2080522T1/en
Priority to DK06778810T priority patent/DK1904099T3/en
Priority to EP09152313A priority patent/EP2080522B1/en
Priority to SI200630298T priority patent/SI1904099T1/en
Priority to DE602006005671T priority patent/DE602006005671D1/en
Priority to ES06778810T priority patent/ES2322102T3/en
Priority to AU2006268466A priority patent/AU2006268466B2/en
Priority to BRPI0614053-0A priority patent/BRPI0614053A2/en
Priority to PCT/FR2006/001635 priority patent/WO2007006939A2/en
Priority to SG201004919-5A priority patent/SG163584A1/en
Priority to PL06778810T priority patent/PL1904099T3/en
Priority to CA2613732A priority patent/CA2613732C/en
Priority to CN2006800248369A priority patent/CN101217977B/en
Priority to JP2008519966A priority patent/JP5300475B2/en
Priority to PL09152313T priority patent/PL2080522T3/en
Priority to MX2007016412A priority patent/MX2007016412A/en
Publication of FR2888117A1 publication Critical patent/FR2888117A1/en
Priority to IL187967A priority patent/IL187967A0/en
Priority to TNP2008000001A priority patent/TNSN08001A1/en
Priority to NO20080585A priority patent/NO336369B1/en
Priority to CY20091100455T priority patent/CY1108994T1/en
Publication of FR2888117B1 publication Critical patent/FR2888117B1/en
Application granted granted Critical
Priority to CY20121100915T priority patent/CY1113414T1/en
Priority to US14/193,097 priority patent/US20140178478A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0507240A 2005-07-07 2005-07-07 VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION Expired - Fee Related FR2888117B1 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (en) 2005-07-07 2005-07-07 VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION
ARP060102917A AR054822A1 (en) 2005-07-07 2006-07-06 ADMISSION IMMUNE EMULSION
BRPI0614053-0A BRPI0614053A2 (en) 2005-07-07 2006-07-07 adjuvant oil-in-water emulsion, use of said emulsion, process for preparing an immunogenic composition comprising at least one vaccine antigen and an oil-in-water emulsion, and immunogenic composition
PT06778810T PT1904099E (en) 2005-07-07 2006-07-07 Thermoreversible immuno- adjuvant emulsion
NZ564173A NZ564173A (en) 2005-07-07 2006-07-07 Thermoreversible immunological adjuvant emulsion
AT06778810T ATE424845T1 (en) 2005-07-07 2006-07-07 THERMOREVERSIBLE IMMUNADJUVANT EMULSION
US11/483,358 US8703095B2 (en) 2005-07-07 2006-07-07 Immuno-adjuvant emulsion
ZA200800824A ZA200800824B (en) 2005-07-07 2006-07-07 Themoreversible immuno-adjuvant emulsion
EA200800271A EA012376B1 (en) 2005-07-07 2006-07-07 Immuno-adjuvant emulsion
AP2007004280A AP2361A (en) 2005-07-07 2006-07-07 Immunological adjuvant emulsion.
PT09152313T PT2080522E (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
KR1020087002704A KR101328638B1 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
EP06778810A EP1904099B1 (en) 2005-07-07 2006-07-07 Thermoreversible immuno- adjuvant emulsion
SI200631423T SI2080522T1 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
PCT/FR2006/001635 WO2007006939A2 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
EP09152313A EP2080522B1 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
SI200630298T SI1904099T1 (en) 2005-07-07 2006-07-07 Thermoreversible immuno- adjuvant emulsion
DE602006005671T DE602006005671D1 (en) 2005-07-07 2006-07-07 Thermoreversible immunadjuvansemulsion
ES09152313T ES2390104T3 (en) 2005-07-07 2006-07-07 Thermoreversible immunoadjuvant emulsion
ES06778810T ES2322102T3 (en) 2005-07-07 2006-07-07 IMMUNE EMULSION-THERMAL-REVERSIBLE ADJUSTER.
AU2006268466A AU2006268466B2 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
DK06778810T DK1904099T3 (en) 2005-07-07 2006-07-07 Thermoreversible immunoadjuvant emulsion
SG201004919-5A SG163584A1 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
PL06778810T PL1904099T3 (en) 2005-07-07 2006-07-07 Thermoreversible immuno- adjuvant emulsion
CA2613732A CA2613732C (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
CN2006800248369A CN101217977B (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
JP2008519966A JP5300475B2 (en) 2005-07-07 2006-07-07 Thermoreversible immune adjuvant emulsion
PL09152313T PL2080522T3 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion
MX2007016412A MX2007016412A (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion.
DK09152313.4T DK2080522T3 (en) 2005-07-07 2006-07-07 Thermoreversible immunoadjuvant emulsion
IL187967A IL187967A0 (en) 2005-07-07 2007-12-06 Thermoreversible immuno-adjuvant emulsion
TNP2008000001A TNSN08001A1 (en) 2005-07-07 2008-01-04 THERMOREVERSIBLE IMMUNO-ADJUVANT EMULSION
NO20080585A NO336369B1 (en) 2005-07-07 2008-01-31 Oil-in-water adjuvant emulsion, use and method of preparation thereof, as well as immunogenic composition and method of preparation thereof.
CY20091100455T CY1108994T1 (en) 2005-07-07 2009-04-27 THERMOSTABLE IMMUNE TREATMENT MILK
CY20121100915T CY1113414T1 (en) 2005-07-07 2012-10-03 THERMOSTABLE IMMUNE TREATMENT MILK
US14/193,097 US20140178478A1 (en) 2005-07-07 2014-02-28 Immuno-Adjuvant Emulsion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (en) 2005-07-07 2005-07-07 VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION

Publications (2)

Publication Number Publication Date
FR2888117A1 FR2888117A1 (en) 2007-01-12
FR2888117B1 true FR2888117B1 (en) 2009-10-09

Family

ID=35871259

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0507240A Expired - Fee Related FR2888117B1 (en) 2005-07-07 2005-07-07 VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION

Country Status (3)

Country Link
AP (1) AP2361A (en)
FR (1) FR2888117B1 (en)
ZA (1) ZA200800824B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (en) * 1989-05-25 1996-03-29 カイロン コーポレイション Adjuvant formulation comprising submicron oil droplet emulsion
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
DK1187629T3 (en) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
WO2002076392A2 (en) * 2001-03-21 2002-10-03 Madash Llc Thermally reversible water in oil in water emulsions

Also Published As

Publication number Publication date
AP2361A (en) 2012-02-06
AP2007004280A0 (en) 2007-12-31
FR2888117A1 (en) 2007-01-12
ZA200800824B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
ATE424845T1 (en) THERMOREVERSIBLE IMMUNADJUVANT EMULSION
DK1968631T3 (en) VACCINE
DE602005019976D1 (en) Screen Printers
NL1028966A1 (en) Projection screen.
DE502005007457D1 (en) MICROEMULSIONS
DE602006000877D1 (en) emulsion composition
NL1028962A1 (en) Projection screen.
DE602005007714D1 (en) NEW QUATERNIZED CHINUCLIDINESTER
DK1957719T3 (en) Pile-driving
DE602005020351D1 (en) IMAGE PROCESSOR
DE602005007554D1 (en) printer
DE602005025430D1 (en) Image character generator
DE502006009397D1 (en) EMULSIFIER COMPOSITION BASED ON PENTAERYTHRRENE
DE602005019579D1 (en) STAPLER
DE602005007527D1 (en) printer
DE602005003531D1 (en) printer
DE602006011850D1 (en) THERMOTRANSFER - RECEPTION SHEET
FR2888117B1 (en) VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION
DE112005003765A5 (en) Triple Image
DE602005007559D1 (en) printer
FR2882926B1 (en) KIT COMPRISING A COSMETIC EMULSION
NL2000179A1 (en) Projection screen.
FR2877600B1 (en) DEMOLITION EMULSION
FR2865114B1 (en) CHEEKY
UA9915S (en) LABEL-ADVERTISING SHEET

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 11

ST Notification of lapse

Effective date: 20170331